299 related articles for article (PubMed ID: 12466165)
1. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
[TBL] [Abstract][Full Text] [Related]
2. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
Simmons ST; Earl ML;
Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
[TBL] [Abstract][Full Text] [Related]
4. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.
Camras CB; Sheu WP;
J Glaucoma; 2005 Apr; 14(2):161-7. PubMed ID: 15741820
[TBL] [Abstract][Full Text] [Related]
5. Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma.
Liu CJ; Ko YC; Cheng CY; Chou JC; Hsu WM; Liu JH
Br J Ophthalmol; 2002 Nov; 86(11):1236-9. PubMed ID: 12386077
[TBL] [Abstract][Full Text] [Related]
6. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
[TBL] [Abstract][Full Text] [Related]
7. Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes.
Thomas R; Parikh R; Muliyil J; George R; Paul P; Abraham LM
Indian J Ophthalmol; 2003 Jun; 51(2):123-8. PubMed ID: 12831141
[TBL] [Abstract][Full Text] [Related]
8. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
[TBL] [Abstract][Full Text] [Related]
10. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
Simmons ST; Samuelson TW
Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
[TBL] [Abstract][Full Text] [Related]
11. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.
Kampik A; Arias-Puente A; O'Brart DP; Vuori ML;
J Glaucoma; 2002 Apr; 11(2):90-6. PubMed ID: 11912355
[TBL] [Abstract][Full Text] [Related]
12. Evaluation and comparison between the effects on intraocular pressure and retinal blood flow of two antiglaucomatous drugs administered in monotherapy: brimonidine and latanoprost. Preliminary results.
Rolle T; Cipullo D; Vizzeri GM; Triggiani A; Brogliatti B
Acta Ophthalmol Scand Suppl; 2000; (232):50-2. PubMed ID: 11235536
[No Abstract] [Full Text] [Related]
13. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
Lee DA; Gornbein JA
J Glaucoma; 2001 Jun; 10(3):220-6. PubMed ID: 11442187
[TBL] [Abstract][Full Text] [Related]
15. Effect of single and multiple doses of 0.2% brimonidine tartrate in the glaucomatous Beagle.
Gelatt KN; MacKay EO
Vet Ophthalmol; 2002 Dec; 5(4):253-62. PubMed ID: 12445295
[TBL] [Abstract][Full Text] [Related]
16. Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma.
Liu CJ; Cheng CY; Ko YC; Hsu WM
J Chin Med Assoc; 2004 Sep; 67(9):465-71. PubMed ID: 15617307
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
18. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle.
Gelatt KN; MacKay EO
Vet Ophthalmol; 2001 Dec; 4(4):283-8. PubMed ID: 11906665
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
[TBL] [Abstract][Full Text] [Related]
20. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination.
Akman A; Cetinkaya A; Akova YA; Ertan A
Eye (Lond); 2005 Feb; 19(2):145-51. PubMed ID: 15184958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
